A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.
Rivastigmine patch is the first transdermal treatment to be approved for Alzheimer's disease (AD) and Parkinson's disease dementia in the USA and for AD in Europe. It provides smooth, continuous drug delivery, and has the potential to maintain rivastigmine concentrations within an optimal therapeutic window while avoiding the peaks and troughs associated with oral drug delivery. The target dose, rivastigmine 9.5 mg/24 h patch (a 10 cm(2) patch), is given once daily and requires a simple one-step dose titration to the therapeutic dose. In a 24-week study in 1195 AD patients, the rivastigmine 9.5 mg/24 h patch provided similar efficacy to the highest dose range of capsules, with approximately three-times fewer reports of nausea and vomiting. Patients in the 9.5 mg/24 h patch and 12 mg/day capsule groups evidenced significant improvements versus placebo on both primary outcome measures: the Alzheimer's Disease Assessment Scale-Cognitive subscale; and Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change; in addition to the following secondary outcome measures: Alzheimer's Disease Cooperative Study-Activities of Daily Living scale; Mini-Mental State Examination; and Trail Making Test Part A for assessment of attention, visual tracking and motor processing speed. Treatment differences on the Neuropsychiatric Inventory and Ten Point Clock-drawing Test did not reach statistical significance in this study. The patch may be the optimal way to treat dementia patients with rivastigmine.
Cummings
Jeffrey
J
UCLA Alzheimer's Center, 10911 Weyburn Avenue, Suite 200, Los Angeles, CA 90095-7226, USA. jcummings@mednet.ucla.edu
Winblad
Bengt
B
D000544:Alzheimer Disease / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D003704:Dementia / Q000097:blood / Q000188:drug therapy / Q000523:psychology; D006801:Humans; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D048448:Phenylcarbamates / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D000068836:Rivastigmine
D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine